Cancer vaccines

Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiller, John T., Lowy, Douglas R., Frazer, Ian H., Finn, Olivera J., Vilar, Eduardo, Lyerly, H. Kim, Gnjatic, Sacha, Zaidi, Neeha, Ott, Patrick A., Balachandran, Vinod P., Dietrich, Pierre-Yves, Migliorini, Denis, Vonderheide, Robert H., Domchek, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Voices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190070/
https://www.ncbi.nlm.nih.gov/pubmed/35700704
http://dx.doi.org/10.1016/j.ccell.2022.05.015
Descripción
Sumario:Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.

Ejemplares similares